Instrument Inactif

Autres langues NeoGenomics, Inc. OTC Bulletin Board

Actions

US64049M2098

Installations et services en soins de santé

Cours en clôture OTC Bulletin Board
- ^USD	-

26/08	NeoGenomics obtient une extension de la couverture Medicare pour le suivi de l'immunothérapie avec RaDaR ST	MT
11/08	NeoGenomics, Inc. annonce la démission d'Alicia Olivo de son poste de directrice juridique, effective au 21 septembre 2026	CI

Autres langues

26/08	NeoGenomics Wins Expanded Medicare Coverage for RaDaR ST Immunotherapy Monitoring
26/08	NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring
11/08	Neogenomics, Inc. Announces Resignation of Alicia Olivo from General Counsel Role, Effective September 21, 2026
06/08	Neogenomics Insider Sold Shares Worth $321,400, According to a Recent SEC Filing
29/07	NeoGenomics Shares Rise After Q2 Beat
28/07	NeoGenomics Q2 Earnings, Revenue Rise; Ups Guidance
28/07	Earnings Flash (NEO) NeoGenomics Posts Q2 Revenue $201.7 Million, vs. FactSet Est of $196.9 Million
28/07	(NEO) NeoGenomics Expects 2026 Revenue Range $802 Million-$806 Million, vs. FactSet Est of $800.4 Million
28/07	Earnings Flash (NEO) NeoGenomics Posts Q2 Adjusted EPS $0.05, vs. FactSet Est of $0.03
28/07	NeoGenomics: Q2 Earnings Snapshot
28/07	NeoGenomics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
28/07	NeoGenomics Reports Second Quarter 2026 Results
28/07	NeoGenomics, Inc. Revises Earnings Guidance for the Full Year Ended December 31, 2026
20/07	NeoGenomics Settles DOJ Investigation Related to Laboratory Collaboration Program
20/07	NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS
20/07	NeoGenomics to Pay $9.8 Million to Resolve Allegations of False Claims Act Violation
09/07	NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic For Prostate Cancer
09/07	NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer
07/07	NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026
25/06	NeoGenomics, Inc. Announces Appointment of Carolyn Starrett to Board of Directors
25/06	NeoGenomics Appoints Carolyn Starrett to its Board of Directors
17/06	NeoGenomics Prices $275 Million Offering of Convertible Notes Due 2032
17/06	NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes
15/06	NeoGenomics Reports Convertible Notes Offering
15/06	NeoGenomics Announces Proposed Offering of $275 Million Convertible Senior Notes